Pulling SEC filings + quote and writing the call…

Monte Rosa Therapeutics, Inc.
Next earnings Aug 5, 2026 · consensus $-0.39 EPS, $5.63M rev
Last earnings -2.8% on 2026-05-07
Revenue grew 63.5% YoY; but unprofitable (net margin -31.2%).
Monte Rosa Therapeutics, Inc. shows $124M in FY2025 revenue (+63.5% YoY), a -31.2% net margin, and -16.6% ROE.
Sources: SEC EDGAR (CIK 0001826457, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 3:12:52 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $75.6M | $124M |
| Gross profit | — | — | — | — | — |
| Operating income | -$72.9M | -$112M | -$143M | -$81.1M | -$54.2M |
| Net income | -$74.0M | -$109M | -$135M | -$72.7M | -$38.6M |
| Diluted EPS | -$2.96 | — | — | — | — |
| Net margin | — | — | — | -96.1% | -31.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 2 sales
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Exercise | 2.18K @ $3.98 | $8.66K |
| 2026-06-17 | Champoux Jennifer Chief Operating Officer | Sell | 2.18K @ $19.00 | $41.3K |
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Exercise | 3.00K @ $6.14 | $18.4K |
| 2026-06-17 | Townson Sharon Chief Scientific Officer | Sell | 3.00K @ $19.00 | $57.0K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.